The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pretreatment serum levels of myeloid-derived suppressor cells (MDSC) are effective as a prognostic indicator in patients with breast cancer.
Kenji Gonda
No relevant relationships to disclose
Masahiko Shibata
No relevant relationships to disclose
Takahiro Nakajima
No relevant relationships to disclose
Yoshiko Matsumoto
No relevant relationships to disclose
Noriko Abe
No relevant relationships to disclose
Tohru Ohtake
No relevant relationships to disclose
Tatsuo Shimura
No relevant relationships to disclose
Seiichi Takenoshita
No relevant relationships to disclose